Welcome to our dedicated page for Aeterna Zentaris news (Ticker: AEZS), a resource for investors and traders seeking the latest updates and insights on Aeterna Zentaris stock.
Aeterna Zentaris, Inc. (AEZS) delivers innovative therapies in endocrinology and oncology through integrated drug development. This news hub provides investors and healthcare professionals with essential updates on the company’s progress.
Access real-time press releases covering clinical trial milestones, regulatory submissions, and strategic partnerships. Our curated feed ensures you never miss critical developments in AEZS’s pipeline, including novel cancer therapies and endocrine disorder treatments.
Key updates include FDA correspondence, research collaborations, financial results, and intellectual property advancements. All content is verified through primary sources to maintain accuracy in this fast-moving sector.
Bookmark this page for streamlined tracking of Aeterna Zentaris’ scientific and corporate developments. Combine regular visits with portfolio monitoring tools for informed decision-making in biopharmaceutical investments.
Aeterna Zentaris reported a net loss of $2.6 million for Q1 2022, compared to $1.5 million in Q1 2021. Revenues decreased to $1.5 million from $1.7 million year-over-year. The company ended the quarter with $63.6 million in cash, expected to fund operations through 2023. Aeterna highlighted progress in its AIM Biologicals programs for treating Parkinson's and neuromyelitis optica spectrum disorder, with upcoming presentations at scientific conferences. The company also secured a European patent for macimorelin across 27 countries.
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that pre-clinical study results of its AIM Biologicals for Parkinson's Disease (PD) were accepted for presentation at IMMUNOLOGY2022. The studies, featuring α-synuclein peptides, show potential in preventing neuron loss in an animal model of PD. The presentation will be led by Prof. Joerg Wischhusen at the Oregon Convention Center on May 6-7, 2022. Aeterna aims to explore AIM Biologicals' therapeutic potential, supported by positive pre-clinical results indicating mobility improvements and neuron rescue in treated PD mice.
Aeterna Zentaris has strengthened its intellectual property portfolio by securing a European patent for macimorelin, the active ingredient in Ghryvelin® / Macrilen™, across 27 EU countries and the UK and Turkey. This patent, extending until 2038, protects the use of macimorelin for diagnosing adult growth hormone deficiency (GHD). The company aims to enhance protection by entering the national phase in 41 European countries, benefiting its licensing partner, Consilient Health. Macimorelin is the only FDA and European Commission approved oral diagnostic for GHD.
JTC Team continues its Virtual Investor Spotlight Series on April 14, 2022, featuring presentations from Aeterna Zentaris (NASDAQ:AEZS), CNS Pharmaceuticals (NASDAQ:CNSP), and American Resources Corporation (NASDAQ:AREC). The series highlights Aeterna's pre-clinical pipeline addressing unmet medical needs, CNS's advancements in treating Glioblastoma, and discussions on national security regarding rare earth elements with American Resources. Live webcasts will be available, providing insights into these companies and their ongoing projects.
Aeterna Zentaris (NASDAQ: AEZS), a biopharmaceutical company, will host a live moderated video webcast featuring CEO Dr. Klaus Paulini and CFO Giuliano La Fratta on April 14, 2022, at 10:00 AM ET. The event will cover the company’s pre-clinical pipeline, targeting conditions like neuromyelitis optica, Parkinson's disease, and amyotrophic lateral sclerosis. A key highlight includes a discussion on an oral vaccine for SARS-CoV-2. The event can be accessed through the company’s website, with a replay available after the presentation.
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that their AIM Biologicals for neuromyelitis optica spectrum disorder (NMOSD) has been accepted for presentation at the 13th International Congress on Autoimmunity in Athens, Greece, from June 10-13, 2022. The research, presented by Dr. Valentin Bruttel, highlights the potential of AIM Biologicals in inducing specific regulatory T cells, showcasing promising pre-clinical results. NMOSD is a serious CNS disorder affecting roughly 10,000 to 15,000 patients in the U.S. and Europe, with a critical need for new therapeutic options.
Aeterna Zentaris Inc. (NASDAQ: AEZS) reported financial results for the year ended December 31, 2021, revealing a consolidated net loss of $8.4 million, or $0.07 per share, compared to a loss of $5.1 million in 2020. The company's total revenue increased to $5.3 million, up from $3.7 million, primarily driven by development service growth. Aeterna ended the year with $65.3 million in cash, expected to fund operations through 2023. The company is advancing a diversified pipeline, including new therapies for neuromyelitis optica and Parkinson's disease, and a COVID-19 vaccine in development.
Aeterna Zentaris has initiated its pivotal Phase 3 safety and efficacy study, AEZS-130-P02, for macimorelin, aimed at diagnosing childhood-onset growth hormone deficiency (CGHD). The study, part of the Pediatric Investigation Plan agreed with regulatory agencies, plans to enroll approximately 100 participants aged 2 to 18 years. With patient enrollment on track for this quarter, completion of the study is anticipated in Q3 2022. Positive preliminary results from a previous study indicate a favorable pharmacokinetic profile for macimorelin.
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that CEO Dr. Klaus Paulini will present at the Q2 Virtual Investor Summit on May 17, 2021 at 8:45 AM ET. The event will include a live video webcast accessible on the Company's website. Management will also hold one-on-one virtual meetings with registered investors. Aeterna is a biopharmaceutical company focused on unmet medical needs, with its lead product macimorelin, the only approved oral test for adult growth hormone deficiency. The company is advancing a pipeline addressing various conditions.
Aeterna Zentaris has announced the selection of AEZS-150 as the lead candidate for its delayed clearance parathyroid hormone (PTH) program in collaboration with the University of Sheffield. This candidate aims to provide a new treatment option for primary hypoparathyroidism.
The company is moving into formal preclinical development, with plans for an IND filing for first-in-human studies. AEZS-150 aims for self-administration via a pen, helping patients maintain normal calcium and phosphate levels.
FAQ
What is the current stock price of Aeterna Zentaris (AEZS)?
What is the market cap of Aeterna Zentaris (AEZS)?
